Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Johann Mittermueller"'
Autor:
Beate Niemeier, Michael Neise, Christoph Losem, Johanna Harde, Ali Aldaoud, Johann Mittermueller, Wolfgang Knauf, Karin Potthoff, Tanja Trarbach
Publikováno v:
Leukemia Research. 68:90-97
Lenalidomide (LEN) is an immunomodulatory drug with significant clinical activity against relapsed and refractory multiple myeloma (r/r MM). Based on the pivotal phase 3 trials MM-009 and MM-010, LEN in combination with dexamethasone (DEX) is approve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd6fc8d462fbcbc634039ec6cf7cc180
https://doi.org/10.1016/j.leukres.2018.03.008
https://doi.org/10.1016/j.leukres.2018.03.008
Autor:
Dominik Paul Modest, Daniel Oruzio, Klaus Zellmann, S. Klein, Thomas Decker, Johann Mittermueller, Volker Heinemann, M. Schulze, Sebastian Stintzing, Wolfgang Abenhardt, Ruediger P. Laubender, Ludwig Fischer von Weikersthal, Hermann F. Dietzfelbinger, Gerhard Puchtler, Holger G. Hass, Martina Stauch, Ursula Vehling-Kaiser, Ulrich Mansmann, Herbert W. Kappauf, Christopher Haberl
Publikováno v:
Journal of Clinical Oncology. 30:3588-3588
3588 Background: This study investigated the impact of early tumor-shrinkage (ETS) on progression-free (PFS) and overall survival (OS) in patients with metastatic colorectal cancer (mCRC) treated within the AIO KRK-0104-trial. ETS was previously show
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8c9696c66d79dc0b59051fb98948118d
https://doi.org/10.1200/jco.2012.30.15_suppl.3588
https://doi.org/10.1200/jco.2012.30.15_suppl.3588